FDA paused trials for experimental drugs more often in recent years

Published



The Food and Drug Administration has increasingly exercised its power to delay drug companies’ testing of experimental drugs in recent years, a possible byproduct of newer medical technologies that offer promise but may pose additional risks.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.